A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma

Gene integrated set profile analysis: a context-based approach for inferring biological endpoints

(2016) Jeanne Kowalski et al.   NUCLEIC ACIDS RESEARCH

Myeloma today: Disease definitions and treatment advances

(2015) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

(2015) P. G. Richardson et al.   BLOOD

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors

(2015) A K Mitra et al.   LEUKEMIA

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

(2015) S K Kumar et al.   Blood Cancer Journal

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

(2014) M. Gambella et al.   HAEMATOLOGICA

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

(2014) H A F Stessman et al.   LEUKEMIA

Learning from exceptional drug responders

(2014) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management

(2013) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Carfilzomib

(2013) K. M. Kortuem et al.   BLOOD

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

New Strategies in the Treatment of Multiple Myeloma

(2013) N. C. Munshi et al.   CLINICAL CANCER RESEARCH

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

(2013) H. A. F. Stessman et al.   MOLECULAR CANCER THERAPEUTICS

Intracellular NAD+depletion induces autophagic death in multiple myeloma cells

(2012) Michele Cea et al.   Autophagy

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs

(2012) J. J.G. Marin et al.   CURRENT CANCER DRUG TARGETS

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

A gene expression signature for high-risk multiple myeloma

(2012) R Kuiper et al.   LEUKEMIA

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Genetic variations in multiple myeloma II: association with effect of treatment

(2011) Annette Vangsted et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

RNF170 Protein, an Endoplasmic Reticulum Membrane Ubiquitin Ligase, Mediates Inositol 1,4,5-Trisphosphate Receptor Ubiquitination and Degradation

(2011) Justine P. Lu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma

(2011) Constantine S. Mitsiades et al.   JOURNAL OF CLINICAL ONCOLOGY

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

(2010) J. Moreaux et al.   HAEMATOLOGICA

Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells

(2010) Sonya G. Fonseca et al.   JOURNAL OF CLINICAL INVESTIGATION

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Random survival forests

(2008) Hemant Ishwaran et al.   Annals of Applied Statistics

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone

(2008) F. Zhan et al.   BLOOD

Many facets of bortezomib resistance/susceptibility

(2008) S. Kumar et al.   BLOOD